Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia

L. M. Lee, C. C. Pan, C. J. Cheng, C. W. Chi, T. Y. Liu

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Elevated expression of cyclo-oxygenase (COX)-2 has been found in several human cancers, including prostate adenocarcinoma. To evaluate the potential prognostic role of COX-2 in prostate cancer, we assessed the expression of COX-2 in benign prostatic hyperplasia (BPH) and prostate cancer samples employing immunohistochemistry. COX-2 was over-expressed in 15 out of 18 (83%) prostate cancer samples whereas it was detected in only 22% (4 of 18) paired benign tissues. The intensity of immunostaining correlated with the tumor grading. In addition, COX-2 was expressed in 7 of the 22 (32%) BPH samples examined. The significance a COX-2 expression in the BPH samples is not known at present. This data suggest that COX-2 is over-expressed in prostate cancer and COX-2 inhibitors may be useful in combination chemotherapy or chemoprevention for prostate cancer.

Original languageEnglish
Pages (from-to)1291-1294
Number of pages4
JournalAnticancer Research
Volume21
Issue number2 B
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

Prostatic Hyperplasia
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases
Prostate
Prostatic Neoplasms
Adenocarcinoma
Cyclooxygenase Inhibitors
Neoplasm Grading
Chemoprevention
Combination Drug Therapy
Immunohistochemistry

Keywords

  • Benign prostatic hyperplasia
  • Cyclooxygenase-2
  • Expression
  • Prostate cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. / Lee, L. M.; Pan, C. C.; Cheng, C. J.; Chi, C. W.; Liu, T. Y.

In: Anticancer Research, Vol. 21, No. 2 B, 2001, p. 1291-1294.

Research output: Contribution to journalArticle

Lee, LM, Pan, CC, Cheng, CJ, Chi, CW & Liu, TY 2001, 'Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia', Anticancer Research, vol. 21, no. 2 B, pp. 1291-1294.
Lee, L. M. ; Pan, C. C. ; Cheng, C. J. ; Chi, C. W. ; Liu, T. Y. / Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia. In: Anticancer Research. 2001 ; Vol. 21, No. 2 B. pp. 1291-1294.
@article{89aa1c7005484b1ba791264e0461bc18,
title = "Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia",
abstract = "Elevated expression of cyclo-oxygenase (COX)-2 has been found in several human cancers, including prostate adenocarcinoma. To evaluate the potential prognostic role of COX-2 in prostate cancer, we assessed the expression of COX-2 in benign prostatic hyperplasia (BPH) and prostate cancer samples employing immunohistochemistry. COX-2 was over-expressed in 15 out of 18 (83{\%}) prostate cancer samples whereas it was detected in only 22{\%} (4 of 18) paired benign tissues. The intensity of immunostaining correlated with the tumor grading. In addition, COX-2 was expressed in 7 of the 22 (32{\%}) BPH samples examined. The significance a COX-2 expression in the BPH samples is not known at present. This data suggest that COX-2 is over-expressed in prostate cancer and COX-2 inhibitors may be useful in combination chemotherapy or chemoprevention for prostate cancer.",
keywords = "Benign prostatic hyperplasia, Cyclooxygenase-2, Expression, Prostate cancer",
author = "Lee, {L. M.} and Pan, {C. C.} and Cheng, {C. J.} and Chi, {C. W.} and Liu, {T. Y.}",
year = "2001",
language = "English",
volume = "21",
pages = "1291--1294",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia

AU - Lee, L. M.

AU - Pan, C. C.

AU - Cheng, C. J.

AU - Chi, C. W.

AU - Liu, T. Y.

PY - 2001

Y1 - 2001

N2 - Elevated expression of cyclo-oxygenase (COX)-2 has been found in several human cancers, including prostate adenocarcinoma. To evaluate the potential prognostic role of COX-2 in prostate cancer, we assessed the expression of COX-2 in benign prostatic hyperplasia (BPH) and prostate cancer samples employing immunohistochemistry. COX-2 was over-expressed in 15 out of 18 (83%) prostate cancer samples whereas it was detected in only 22% (4 of 18) paired benign tissues. The intensity of immunostaining correlated with the tumor grading. In addition, COX-2 was expressed in 7 of the 22 (32%) BPH samples examined. The significance a COX-2 expression in the BPH samples is not known at present. This data suggest that COX-2 is over-expressed in prostate cancer and COX-2 inhibitors may be useful in combination chemotherapy or chemoprevention for prostate cancer.

AB - Elevated expression of cyclo-oxygenase (COX)-2 has been found in several human cancers, including prostate adenocarcinoma. To evaluate the potential prognostic role of COX-2 in prostate cancer, we assessed the expression of COX-2 in benign prostatic hyperplasia (BPH) and prostate cancer samples employing immunohistochemistry. COX-2 was over-expressed in 15 out of 18 (83%) prostate cancer samples whereas it was detected in only 22% (4 of 18) paired benign tissues. The intensity of immunostaining correlated with the tumor grading. In addition, COX-2 was expressed in 7 of the 22 (32%) BPH samples examined. The significance a COX-2 expression in the BPH samples is not known at present. This data suggest that COX-2 is over-expressed in prostate cancer and COX-2 inhibitors may be useful in combination chemotherapy or chemoprevention for prostate cancer.

KW - Benign prostatic hyperplasia

KW - Cyclooxygenase-2

KW - Expression

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0035011423&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035011423&partnerID=8YFLogxK

M3 - Article

C2 - 11396201

AN - SCOPUS:0035011423

VL - 21

SP - 1291

EP - 1294

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -